PT3533796T - Composto de amino pirazolopirimidina utilizado como inibidor do recetor do fator neurotrófico tirosina quinase - Google Patents

Composto de amino pirazolopirimidina utilizado como inibidor do recetor do fator neurotrófico tirosina quinase

Info

Publication number
PT3533796T
PT3533796T PT178634101T PT17863410T PT3533796T PT 3533796 T PT3533796 T PT 3533796T PT 178634101 T PT178634101 T PT 178634101T PT 17863410 T PT17863410 T PT 17863410T PT 3533796 T PT3533796 T PT 3533796T
Authority
PT
Portugal
Prior art keywords
tyrosine kinase
compound used
neurotrophic factor
receptor inhibitor
kinase receptor
Prior art date
Application number
PT178634101T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Lianyungang Runzhong Pharmaceutical Co Ltd
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lianyungang Runzhong Pharmaceutical Co Ltd, Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Lianyungang Runzhong Pharmaceutical Co Ltd
Publication of PT3533796T publication Critical patent/PT3533796T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT178634101T 2016-10-28 2017-10-27 Composto de amino pirazolopirimidina utilizado como inibidor do recetor do fator neurotrófico tirosina quinase PT3533796T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610970314 2016-10-28
CN201710044000 2017-01-21

Publications (1)

Publication Number Publication Date
PT3533796T true PT3533796T (pt) 2021-11-18

Family

ID=62024344

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178634101T PT3533796T (pt) 2016-10-28 2017-10-27 Composto de amino pirazolopirimidina utilizado como inibidor do recetor do fator neurotrófico tirosina quinase

Country Status (15)

Country Link
US (1) US10829492B2 (https=)
EP (1) EP3533796B1 (https=)
JP (1) JP7046940B2 (https=)
KR (1) KR102616249B1 (https=)
CN (1) CN109890820B (https=)
AU (1) AU2017348826B2 (https=)
CA (1) CA3041942C (https=)
DK (1) DK3533796T3 (https=)
ES (1) ES2896943T3 (https=)
HU (1) HUE057733T2 (https=)
MX (1) MX380283B (https=)
PL (1) PL3533796T3 (https=)
PT (1) PT3533796T (https=)
RU (1) RU2764523C2 (https=)
WO (1) WO2018077246A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286264B2 (en) * 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
DK3674307T3 (da) 2017-08-23 2023-09-11 Chia Tai Tianqing Pharmaceutical Group Co Ltd Makrocyklus indeholdende aminopyrazol og pyrimidin og farmaceutisk sammensætning og anvendelse deraf
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
CA3122136A1 (en) * 2018-12-07 2021-06-11 Betta Pharmaceuticals Co., Ltd Tyrosine kinase inhibitors, compositions and methods there of
JP7209415B2 (ja) 2019-03-19 2023-01-20 セントラル チャイナ ノーマル ユニバーシティ ピラゾロピリミジン化合物、医薬組成物、及びその使用
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业(成都)有限公司 杂芳基稠环化合物、其制备方法及应用
TW202214635A (zh) * 2020-06-11 2022-04-16 大陸商貝達藥業股份有限公司 酪氨酸激酶抑制劑的鹽型、晶型、藥物組合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
CN114437075B (zh) * 2020-11-03 2026-01-30 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
CN113200963A (zh) * 2021-03-31 2021-08-03 广东石油化工学院 N-(吡咯基)-3-吡唑基胺及其制备方法
JP7840066B2 (ja) * 2021-05-03 2026-04-03 ジェービーケーラボ カンパニー リミテッド 2,6-ジクロロ-4-(4-(4-ヒドロキシシクロヘキシルアミノ)-7h-ピロロ[2,3-d]ピリミジン-5-イル)フェノールを活性成分として含有する、がんを予防、緩和、または処置するための医薬組成物
CN117751121A (zh) * 2021-07-30 2024-03-22 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物的晶体
WO2023011616A1 (zh) * 2021-08-06 2023-02-09 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁(上海)医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
WO2009140128A2 (en) 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) * 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
KR20140105508A (ko) * 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104650092B (zh) * 2013-11-16 2017-11-10 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
DK3077397T3 (da) * 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
CA2971024C (en) 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors

Also Published As

Publication number Publication date
PL3533796T3 (pl) 2022-01-17
CN109890820B (zh) 2020-11-03
US10829492B2 (en) 2020-11-10
MX380283B (es) 2025-03-12
KR102616249B1 (ko) 2023-12-21
EP3533796B1 (en) 2021-09-29
RU2019114600A3 (https=) 2021-02-20
US20190352306A1 (en) 2019-11-21
CA3041942C (en) 2023-03-14
MX2019004847A (es) 2019-08-29
KR20190067913A (ko) 2019-06-17
BR112019008656A8 (pt) 2022-06-07
ES2896943T3 (es) 2022-02-28
WO2018077246A1 (zh) 2018-05-03
AU2017348826B2 (en) 2021-12-02
DK3533796T3 (da) 2021-11-08
EP3533796A4 (en) 2020-06-03
BR112019008656A2 (pt) 2019-07-09
EP3533796A1 (en) 2019-09-04
RU2019114600A (ru) 2020-11-30
JP7046940B2 (ja) 2022-04-04
JP2019537588A (ja) 2019-12-26
CA3041942A1 (en) 2018-05-03
CN109890820A (zh) 2019-06-14
AU2017348826A1 (en) 2019-05-23
HUE057733T2 (hu) 2022-06-28
RU2764523C2 (ru) 2022-01-18

Similar Documents

Publication Publication Date Title
PT3533796T (pt) Composto de amino pirazolopirimidina utilizado como inibidor do recetor do fator neurotrófico tirosina quinase
IL279258B (en) tyrosine kinase inhibitors
ZA202000395B (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
ZA201808431B (en) Pyrazolopyrimidine derivatives as kinase inhibitor
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
ZA201807179B (en) Pyrimidine compounds as jak kinase inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL265829B (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
HUE049502T2 (hu) Policiklusos vegyületek mint bruton-tirozin-kináz inhibitorok
IL273443A (en) Bicyclic compounds for use as RIP1 kinase inhibitors
IL304547A (en) 3-substituted benzamide derivatives as kinase inhibitors
IL257625A (en) Tricyclic compounds are concentrated as kinase protein inhibitors
IL269144A (en) Pyrrolotriazine derivatives as kinase inhibitors
HK40037119A (en) Pyrimidine compounds useful as tyrosine kinase inhibitors
EP3727387A4 (en) PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
IL272887A (en) A pharmaceutical preparation containing a selective inhibitor of FGFR tyrosine kinase
GB201613945D0 (en) Compounds useful as kinase inhibitors